Finally, the programmed death‐ligand 1 (PD‐L1) assessment evaluated by immunohistochemistry (IHC) as tumor proportion score (TPS), is one of the required indicators to select NSCLC patients for immune checkpoint inhibitor therapy.11 This evidence concerns the gene CD274 and neoplasm.